Rules & Guidelines for Abstract Submission

General Rules:

• •       Abstracts must be submitted in English via the ISCO website only. Submission guarantees free registration to ISCO 2026. Abstracts received after the deadline will not be considered.

  •       The email used for the presenting author at submission must match the email used during registration.

  •       The same person may serve as presenting author on up to 2 abstracts.

  •       The Scientific Committee will determine whether accepted abstracts are displayed as e-Posters. The top 2 highest-scored abstracts will be selected for oral presentation.

  •       The single best oral presentation will win the ISCO GOT RESEARCHERS prize of $1,000.

  •       Up to 5 winning abstracts will be considered for publication in OncoDaily, an international open-access oncology journal.

  •       The 2 selected oral presentations will take place during the Research Workshop in Hall B, Friday, April 24th, before an international panel of expert researchers.

  •       Oral presentations are in-person at Cairo Marriott Hotel, Zamalek. Foreign participants unable to attend may present virtually — indicate this preference at submission.

  •       Being selected for e-Poster or oral presentation does not guarantee a travel grant, airfare, or accommodation.

  •       Acceptance and rejection notifications will be sent to the corresponding author by email.

  Submission Guidelines

  Required information:

  ◦       Presenting author: full name, email, affiliation (department, institution, city, country), phone number

  ◦       All co-authors: full names and affiliations

  ◦       Abstract title — UPPER CASE, max 25 words

  ◦       Abstract text — max 300 words, structured as: Introduction & Objectives / Materials & Methods / Results / Conclusions

  ◦       Abstract topic — select one from the list below

  Topics:

  ◦       All Solid Tumors related research

  ◦       Hematologic Malignancies

  ◦       Developmental Therapeutics — Immunotherapy, Targeted Therapies and Tumor Biology

  ◦       Symptom Science and Palliative Care

  ◦       Quality Care / Health Services Research

  ◦       Prevention, Risk Reduction, and Genetics

  ◦       Care Delivery / Models of Care

  Submission standards:

  •       Use generic drug names. No commercial or promotional content.

  •       Abstracts must contain data and meet international ethical standards. Case reports will not be accepted.

  •       No patient names, hospital IDs, or identifying information.

  •       Statements such as “results will be discussed” will result in rejection.

  •       Define all abbreviations. The abstract will be published exactly as submitted — no proofreading will be performed.

  •       Do not submit duplicate copies.

  Cancellation

  Cancellations must be submitted by the principal author via email to the ISCO Scientific Committee no later than April 20th, 2026.

  Authors’ Agreement

  By submitting, all authors confirm that:

  •       They have conducted the work described and take full responsibility for its content.

  •       All authors approve submission and agree to confine the presentation to the abstract’s content.

  •       Clinical studies have received official ethical and regulatory approval.

  •       The presenting author is a registered congress participant.

  •       The Scientific Committee will be notified immediately if the presenting author changes or is unable to present.

  •       The abstract may not be modified after final submission and will be published as submitted.

  •       The Organizers are granted a royalty-free, perpetual, non-exclusive license to reproduce, publish, and distribute the abstract.

  The Organizers reserve the right to remove any abstract from publication or presentation for non-compliance with these guidelines.